CN111601797A - 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用 - Google Patents

苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN111601797A
CN111601797A CN201980008818.9A CN201980008818A CN111601797A CN 111601797 A CN111601797 A CN 111601797A CN 201980008818 A CN201980008818 A CN 201980008818A CN 111601797 A CN111601797 A CN 111601797A
Authority
CN
China
Prior art keywords
group
compound
groups
cycloalkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980008818.9A
Other languages
English (en)
Other versions
CN111601797B (zh
Inventor
杨方龙
李晓东
王伟民
陈刚
贺峰
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Chengdu Suncadia Pharmaceuticals Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN111601797A publication Critical patent/CN111601797A/zh
Application granted granted Critical
Publication of CN111601797B publication Critical patent/CN111601797B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用。特别地，本发明涉及通式(I)所示的苯并哌啶类衍生物或杂芳基并哌啶类衍生物、其制备方法及含有该衍生物的药物组合物，以及其作为雌激素受体调节剂预防和/或治疗雌激素受体介导的或依赖性的疾病或病症的用途，所述的疾病特别优选乳腺癌。其中通式(I)中的各取代基同说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (27)

  1. PCT国内申请，权利要求书已公开。
CN201980008818.9A 2018-05-23 2019-05-22 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用 Active CN111601797B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018105034750 2018-05-23
CN201810503475 2018-05-23
CN2019101487703 2019-02-28
CN201910148770 2019-02-28
PCT/CN2019/087944 WO2019223715A1 (zh) 2018-05-23 2019-05-22 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN111601797A true CN111601797A (zh) 2020-08-28
CN111601797B CN111601797B (zh) 2022-11-22

Family

ID=68615919

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980008818.9A Active CN111601797B (zh) 2018-05-23 2019-05-22 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用

Country Status (3)

Country Link
CN (1) CN111601797B (zh)
TW (1) TW202003495A (zh)
WO (1) WO2019223715A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021143822A1 (zh) * 2020-01-16 2021-07-22 江苏恒瑞医药股份有限公司 并环酰亚胺类衍生物、其制备方法及其在医药上的应用
WO2021143816A1 (zh) * 2020-01-16 2021-07-22 江苏恒瑞医药股份有限公司 稠合酰亚胺类衍生物、其制备方法及其在医药上的应用
US20230348459A1 (en) * 2020-05-15 2023-11-02 Simcere Pharmaceutical Co., Ltd. Pyrrolidine compound and use thereof
CN114105977B (zh) * 2020-08-28 2023-09-01 先声再明医药有限公司 雌激素受体调节剂化合物及其用途
EP4267578A1 (en) 2020-12-23 2023-11-01 Recurium IP Holdings, LLC Estrogen receptor modulators
CN113024460B (zh) * 2021-03-10 2022-11-08 中国药科大学 作为雌激素受体与组蛋白去乙酰化酶双靶点化合物的四氢异喹啉类化合物、合成方法及用途
EP4310079A1 (en) * 2021-03-15 2024-01-24 Shenzhen Forward Pharmaceuticals Co., Limited Estrogen receptor antagonist
CN118251392A (zh) * 2021-11-12 2024-06-25 南京再明医药有限公司 吡咯烷类化合物的盐、晶型及其制备方法
WO2024017131A1 (zh) * 2022-07-21 2024-01-25 贝达药业股份有限公司 杂芳基并哌啶类衍生物及其药物组合物和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138659A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating brain tumors
WO2015092634A1 (en) * 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
WO2017107754A1 (zh) * 2015-12-22 2017-06-29 江苏恒瑞医药股份有限公司 苯并哌啶类衍生物、其制备方法及其在医药上的应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138659A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating brain tumors
WO2015092634A1 (en) * 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
WO2017107754A1 (zh) * 2015-12-22 2017-06-29 江苏恒瑞医药股份有限公司 苯并哌啶类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
TW202003495A (zh) 2020-01-16
CN111601797B (zh) 2022-11-22
WO2019223715A1 (zh) 2019-11-28

Similar Documents

Publication Publication Date Title
CN111601797B (zh) 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用
TWI718207B (zh) 苯並呋喃類衍生物、其製備方法及其在醫藥上的應用
TWI756257B (zh) 吡啶酮醯胺類衍生物、其製備方法及其在醫藥上的應用
TWI714600B (zh) 哌啶類衍生物、其製備方法及其在醫藥上的應用
WO2021031952A1 (zh) 氧代六元环并嘧啶类化合物，其制法与医药上的用途
US10398689B2 (en) Benzopiperidine derivative, preparation method thereof and medical use thereof
TW202115089A (zh) 喹唑啉酮類衍生物、其製備方法及其在醫藥上的應用
CN112778276A (zh) 作为shp2抑制剂的化合物及其应用
WO2020238791A1 (zh) 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
CN114805462A (zh) 一种甾族类衍生物调节剂及其制备方法和应用
WO2022268230A1 (zh) 作为kif18a抑制剂的化合物
WO2006033318A1 (ja) 環状アミン誘導体又はその塩
WO2022206737A1 (zh) 四氢萘类化合物、其制备方法及其在医药上的应用
WO2021208918A1 (zh) 作为egfr抑制剂的三环化合物
WO2022166879A1 (zh) 苯并七元环类双功能化合物及其应用
WO2022194269A1 (zh) 新型egfr降解剂
CN113874367A (zh) 吲唑类衍生物、其制备方法及其在医药上的应用
TWI422578B (zh) 縮合茚滿化合物
TW202045493A (zh) ２－胺基嘧啶類衍生物、其製備方法及其在醫藥上的應用
JPH08506817A (ja) スピロ（２ｈ−１−ベンゾピラン−２，４′−ピペリジン）クラス▲ｉｉｉ▼抗不整脈薬
CN115043836B (zh) 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
CN107200725B (zh) 稠杂环类衍生物、其制备方法及其在医药上的应用
WO2024094171A1 (zh) 取代的氨基嘧啶类化合物、其制备方法及其在医药上的应用
WO2022095971A1 (zh) 一种螺杂环类化合物、其制备方法及应用
WO2024067463A1 (zh) 苯并[7]环烯类衍生物、包含其的药物组合物及其医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20231016

Address after: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Patentee after: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee after: SUNCADIA PHARMACEUTICALS Co.,Ltd.

Patentee after: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

Address before: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Patentee before: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee before: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.